Rapidly fatal advanced <i>EGFR</i>-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

导出 LinkOut

翻译打印收藏纠错

第一作者： Deepa,Rangachari

第一单位： Department of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA, USA.

作者： Deepa,Rangachari ^[1] ; Lauren,Drake ^[1] ; Mark S,Huberman ^[1] ; Danielle C,McDonald ^[1] ; Paul A,VanderLaan ^[2] ; Erik,Folch ^[1] ; Daniel B,Costa ^[1]

作者单位： Department of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA, USA. ^[1] Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School; Boston, MA, USA. ^[2]

关键词 EGFR NSCLC TKI afatinib erlotinib gefitinib

DOI 10.1016/j.ctarc.2016.07.001

PMID 28111612

发布时间 2020-10-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer treatment communications

2016年9卷

41-43页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Rapidly fatal advanced <i>EGFR</i>-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Cancer treatment communications

相似文献

Cancer treatment communications

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Rapidly fatal advanced <i>EGFR</i>-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

Cancer treatment communications

相似文献

Cancer treatment communications

相关期刊

检索历史清除